Bayesian optimal interval designs for phase I clinical trials

type="main" xml:id="rssc12089-abs-0001"> In phase I trials, effectively treating patients and minimizing the chance of exposing them to subtherapeutic and overly toxic doses are clinicians' top priority. Motived by this practical consideration, we propose Bayesian optimal interval (BOIN) designs to find the maximum tolerated dose and to minimize the probability of inappropriate dose assignments for patients. We show, both theoretically and numerically, that the BOIN design not only has superior finite and large sample properties but also can be easily implemented in a simple way similar to the traditional ‘3+3’ design. Compared with the well-known continual reassessment method, the BOIN design yields comparable average performance to select the maximum tolerated dose but has a substantially lower risk of assigning patients to subtherapeutic and overly toxic doses. We apply the BOIN design to two cancer clinical trials.

[1]  Shing M. Lee,et al.  Model calibration in the continual reassessment method , 2009, Clinical trials.

[2]  Oke Gerke,et al.  Optimal phase I dose‐escalation trial designs in oncology—A simulation study , 2008, Statistics in medicine.

[3]  Nancy Flournoy,et al.  Cumulative cohort design for dose-finding , 2007 .

[4]  Nancy Flournoy,et al.  Random Walks for Quantile Estimation , 1994 .

[5]  W J Shih,et al.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.

[6]  Naitee Ting.  Dose Finding in Drug Development , 2006 .

[7]  Yuan Ji,et al.  A modified toxicity probability interval method for dose-finding trials. , 2010, Clinical trials.

[8]  S. Chevret,et al.  Statistical Methods for Dose-Finding Experiments: Chevret/Statistical Methods for Dose-Finding Experiments , 2006 .

[9]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[10]  Xavier Paoletti,et al.  Design efficiency in dose finding studies , 2004, Comput. Stat. Data Anal..

[11]  Ying Kuen Cheung,et al.  Calibration of prior variance in the Bayesian continual reassessment method , 2011, Statistics in medicine.

[12]  S. Chevret,et al.  Statistical methods for dose-finding experiments , 2006 .

[13]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[14]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[15]  N. Hjort,et al.  On Bayesian consistency , 2001 .

[16]  Zhilong Yuan,et al.  Isotonic designs for phase I cancer clinical trials with multiple risk groups , 2004, Clinical trials.

[17]  David Azriel,et al.  Dose-Finding Designs: The Role of Convergence Properties , 2011, The international journal of biostatistics.

[18]  J. M. Bremner,et al.  Statistical Inference under Restrictions , 1973 .

[19]  J Whitehead,et al.  Bayesian decision procedures for dose determining experiments. , 1995, Statistics in medicine.

[20]  D H Leung,et al.  Isotonic designs for phase I trials. , 2001, Controlled clinical trials.

[21]  Mark D Krailo,et al.  Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Anastasia Ivanova,et al.  Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach , 2009, Biometrics.

[23]  Ying Kuen Cheung,et al.  Coherence principles in dose-finding studies , 2005 .

[24]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.